Join the club for FREE to access the whole archive and other member benefits.

Senescent cells: short safety trial on humans successful

Next step is to go to an actual large-scale human trial


Key points from article :

Short safety trial on removing senescent cells from patients with lung fibrosis becomes successful.

There was marked improvement in physical function after nine doses over three weeks.

But lung function, clinical test outcomes, frailty levels and overall health did not change.

Used the senolytic dasatinib plus quercetin, an open-label drug, to clear the senescent cells.

This is only the first step of going into human trials.

A collaborative research published in EBioMedicine.

Mentioned in this article:

Click on resource name for more details.


Medical journal covering all fields in the biomedical research

James Kirkland

Researcher on different aging related diseases

Mayo Clinic

Non-profit American academic medical center focused on health care, education, and research

University of Texas Health

A campus in University of Texas that consists of five schools to train healthcare professionals

Topics mentioned on this page:
Senescent Cells